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Summary: A derivative of luciferin, 4-methyl-ZMuciferin, was synthesized in low yield, and characterized by
its ultraviolet and fluorescence spectra. The spectra of luciferin and its derivative are very similar. 4-Methyl-
ZMuciferin is a substrate of Photinus pyralis luciferase, and it causes light emission in luminometric assays.
Introduction
Firefly luciferase catalyses the ATP-dependent oxida-
tive decarboxylation of D(-)-luciferin, accompanied
by the production of light.
Firefly luciferin, Z)(-)-2-(6/-hydroxy-2/-benzothiazo-
lyl)-2-thiazoline-4-carboxylic acid was first isolated in
pure form from the American firefly Photinus pyralis
in 1957 by Bitler & Me Elroy (1). Luciferin was
subsequently chemically synthesized and character-
ized by White et al. (2).
Many structural analogues of luciferin have been syn-
thesized (3 — 7). All are characterized by substitution
of the carboxyl group or the phenoxide ion. However,
since these two chemical groups are essential for lu-
ciferin light emission properties (8), the synthesized
derivatives are poor substrates or require post modi-
fications (7, 9).
With the aim of constructing luciferin-labelled ma-
cromolecules, in which the luciferin moiety is
branched through a carbon spacer on carbon 4, we
have investigated whether 4-methyl-ZMuciferin be-
haves as a substrate of luciferase. In this paper, we
present the protocol for the synthesis of this com-
pound, and describe its physico-chemical properties
and its light emission properties during luciferase-
catalysed oxidation. It was shown that the methyl-
derivative possesses strong light emission properties,
confirming that substitution on carbon 4 is suitable
for linking to other biomolecules.
Materials and Methods
The products used for synthesis of 4-methyl-ZMuciferin and the
solvents for its purification were purchased from Aldrich-
chimie, France.
Z>-Luciferin (Photinus pyralis), luciferase (Photinus pyralis;
8 U/mg) and ATP were purchased from Boehringer Mannheim,
FRG.
Synthesis of 4-methyl-/)-luciferin
This compound was synthesized by a modification of the White
& Me Capra procedure (1).
4-Methoxy 2-methylaniline is condensed with ethyloxalate to
give the oxamate (I). This compound is converted to the thioam-
ide with phosphorus pentasulphlde and hydrolysed without
isolation to give the thiooxamic acid (II). Oxidation of (II) with
alkaline ferricyanide gives the benzothiazole compound (III),
which is converted into the amide (IV) by treatment with thionyl
chloride, then ammonia. Dehydration with phosphorus oxy-
chloride leads to the nitrile (V). Demethylation of (V) by pyr-
idine hydrochloride gives the phenol (VI). Condensation of (VI)
with D-cysteine gives a low yield of the required luciferin (VII).
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Spectrometry
Ultra-violet spectra were made at room temperature using a
Uvikon 860 spectrophotometer (Kontron Instrument). Fluo-
rescence spectra were made with a spectrofluorimeter JY 3D
(Jobin Yvon) at room temperature. The buffer used in both
cases was 20 mmol/1 TRIS-acetate, pH 7.75, containing 10
mmol/1 magnesium acetate.
Ethyl-N- (4-methoxy 2-methyl-phenyl) oxamate (I)
Ethyioxalate (1.5 mol) was heated to 120 °C. Amine (0.73 mol)
was then added and the temperature of the mixture raised to
180°C for five minutes. After cooling the mixture in an ice
bath, the precipitated solid was collected, then washed with
ethanol and ether; m.p. 94 °C; yield 65%.
HPLC chromatography
We used the following HPLC system: column PROLABO SiC5
(250 χ 4mm); flow 0.6 ml/min; wavelength 270 nm. Eluant:
0.05 mol/1 ammonium acetate (pH 7.0), methanol, volume frac-
tion 0.52.
Determinat ion of enzyme ac t iv i ty
The acticities of luciferin and its derivative as substrates of
luciferase were compared according to the modified procedure
of Miska & Geiger (9). The bioluminometer (Clinilumat LB
9502T) was from Berthold Wildbad, FRG. A solution contain-
ing 2.5 mg/1 luciferase and 10 mmol/1 ATP in 20 mmol/1 TRIS-
acetate, pH 7.75, 10 mmol/1 Mg2+, 0.66 mmol/1 EDTA, 0.1
mmol/1 dithioerythritol, 0.01 g/1 NaN3 and 0.1 g/1 bovine serum
albumin, was preincubated at room temperature for 20 minutes.
One hundred microlitres (100 μΐ) of this solution were then
mixed with the same volume of diluted luciferin or luciferin
derivative; light impulses were integrated for 10 seconds at
25 °C.
Each enzyme substrate was assayed four times independently.
Triplicate determinations were carried out for each assay and
the coefficient of variation was expressed as a percentage of
the mean value.
Results and Discussion
Synthesis of 4-methyl- / ) - lucifer in
Methyl luciferin was synthesized in 7 steps, each in fairly good
yield, except for the last one. They are described on figure 1.
N-(4-Methoxy 2-methyl-phenyl)thiooxamic acid (II)
43 g of (I) were added to 0.9 1 of boiling xylene, followed by
the addition of 14.5 g of phosphorus pentasulphide in small
portions to the boiling solution. Reflux was continued for 2
hours. After cooling, the mixture was extracted with ten 150
ml portions of 1 mol/1 sodium hydroxide. The basic extracts
were filtered, cooled to 0 CC and acidified with concentrated
hydrochloric acid (200 ml). The precipitate was collected and
washed with water. We used this crude material for the oxida-
tion.
6-Methoxy-4-methyl-benzothiazole 2-carboxylic acid (HI)
Crude (II) was dissolved in 1 mol/1 sodium hydroxide (700 ml)
and oxidized with potassium ferricyanide (200 g in 500 ml of
water) by slow addition of the thioxamic acid to the ferricyanide
solution, keeping the temperature of the mixture below 10 °C.
The mixture was filtered and the solid collected. The solid was
suspended in water with stirring, and acidified with concen-
trated hydrochloric acid. A brown solid was precipitated; m. p.
127 °C; yield 66% (from the oxamate); NMR (in DMSO): 7.65
and 7.2 ppm aromatic protons, 3.9 ppm OCH3, 2.7 ppm OCH3.
6-Methoxy-4-methyl-benzothiazole 2-carboxamide (IV)
0.117 mol of (III) and 150 ml of thionyl chloride were refluxed
for two hours. The excess thionylchloride was removed and the
remaining product was dissolved in 200 ml of methylene chlo-
ride. Gaseous ammonia was bubbled through the solution for
4 hours. The precipitate was filtered and washed with water to
yield 10 g (40%) of a solid melting at 205.8 °C.
H3C-0'
H3C-0'
HS-CH2
D-Cysteine
Fig. 1. Reaction scheme for the synthesis of 4-methyl-Z>-luciferin.
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2-Cyano-6-methoxy-4-methyl benzothiazole (V)
We heated a mixture of 0.022 mol of (V) with 30 ml of phos-
phorus oxychloride under reflux, until all the amide had dis-
solved (ca 15 min). The excess phosphorus oxychloride was
removed as completely as possible. The residue was cooled,
ether added and the solution was decomposed with 10 g/1
sodium bicarbonate solution. The pH was adjusted to 6 and
the nitrile was extracted with chloroform.
The chloroform solution was washed with water, dried over
magnesium sulphate, and the solvent evaporated to give 3 g of
an oily product (yield 67%).
2-Cyano-6-hydroxy-4-methyl benzothiazole (VI)
Pyridine hydrochloride (20 g) was heated to 220 °C in an an-
hydrous atmosphere. Then (V) (1.5 g) was added in small por-
tions. The mixture was heated with stirring at 220 °C for an
hour. After cooling, the black solution was decomposed with a
100 g/1 sodium carbonate solution, taking care that the solution
did not become strongly alkaline. The solid was then filtered.
For purification, the crude nitrile was dissolved in ethanol and
passed through a column of charcoal (4 g) and celite (7 g).
Removal of the solvent gave 100 mg (7%) of (VI).
NMR (CD3COCD3) 8.5 ppm OH, 7.4 and 7.1 ppm aromatic
protons, 2.7 ppm CH3.
4-Methyl-D-luciferin (VII)
In a flask of low actinic glass (under a nitrogen atmosphere)
100 mg of Z)-cysteine hydrochloride and 6 ml of 1 g/1 sodium
carbonate solution were mixed with stirring, followed by ad-
dition of 100 mg of (VI) in methanol (5 ml). A precipitate
formed, then redissolved. After an hour the mixture was aci-
dified with 1 mol/1 hydrochloric acid and kept at 0 °C overnight.
Rapid filtration gave a pale yellow solid; yield 10 mg (6.5%).
This product must be protected from light, oxygen and basic
conditions.
Chemical charac ter iza t ion
The luciferin derivative was characterized by ultra-violet and
fluorescence spectrophotometry (see spectra in figs. 2 and 3).
The UV spectrum of luciferin and its derivative are very similar,
indicating that both molecules share the same aromatic struc-
tures. Furthermore, as shown in figure 2, we found that luciferin
and 4-methyl-Z>-luciferin have the same absorption peak at 266
nm. The fluorometric analysis showed identical peaks of exci-
tation and emission (tab. 1). However, we noted that the in-
tensities for 4-methyl-Z)-luciferin were reduced in comparison
with luciferin.
3.000 -
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Fig. 2. Ultraviolet spectra of D-luciferin ( — ) and its synthetic
derivative (—).
Fig. 3. Fluorescence spectra of ZMuciferin (a) and its synthetic
derivative (b) (left: excitation; right: emission).
In high performance liquid chromatography, the synthesized
methylated derivative of luciferin was shown to be homogene-
ous, with a retention time very close to but greater than that
of natural luciferin (data not shown).
Tab. 1. Fluorescence properties of ZMuciferin and 4-methyl-/)-
luciferin.
£>-Luciferin Buffer
derivative
D-Luciferin Γ f 20 mmol/1
1 Tris acetate
4-Methyl-/)- 1
luciferin |^
10 mmol/1
Mg2+
1 5 mmol/1
NaN3, pH 7.75
Exci-
tation
(nm)
341
341
Emis-
sion
(nm)
532
535
Enzymic character izat ion
In our procedure, methyl-luciferin was not synthesized by mod-
ification of luciferin, but by a total synthesis from appropriate
precursors. There is therefore no possibility that luciferin is
present, i.e. light production in the enzymic assay cannot be
due to or affected by traces of luciferin. The ability of methyl-
luciferin to replace the natural substrate in an enzymic assay
was investigated by incubating various amounts of luciferin or
methyl-luciferin with fixed amounts of ATP and luciferase. Ten-
second light impulse intensities are plotted on figure 4. This
shows that the methylated derivative of luciferin is indeed a
substrate of luciferase and that up to 1000 times the background
level can be attained at 3.5 · 10~5 mol/1. Also, as for luciferin,
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10'
ΊΟ·2
10'
light emission depended on the concentration of the synthetic
derivative. Maximum light emission was observed at about the
same concentration of both substrates. At high substrate con-
centration (10~2 mol/1), light emission decreased dramatically.
According to De Luca & Me Elroy (10) this is due to luciferase
inhibition by oxyluciferin, a by-product of the reaction.
Chemical synthesis from ethyloxalate gives a modified deriva-
tive without contamination with the natural substrate, which
is important for the comparison of the two substrates in the
enzymic reaction. As a substrate for light production with
luciferase, methyl-luciferin is highly efficient, although it is
twenty times less efficient than luciferin. This demonstrates that
an additional group in the carbon 4 does not prevent light
emission. Substitution of the methyl group on the aromatic
ring makes it possible to link luciferin to various molecules. We
are now testing the properties of such substrates.
7-10-12 7-10-10 7-10-8 7ΊΟ-6
Substrate [mol/vial]
Fig. 4. Determination of ZMuciferin and its derivative in the
luminometric assay (in assay: 10 mmol/1 ATP, 0.25 μg
luciferase). — indicates the background (assay without
substrate).
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